Sartorius Stedim Biotech (SDMHF) Stock Price, News & Analysis

Company Overview

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.

Key Stats

• Today's Range: $218.00 to $218.00
• 50-Day Range: $173.79 to $226.68
• 52-Week Range: $158.00 to $236.50
• Volume: N/A
• Average Volume: 3,458 shs
• Market Capitalization: N/A
• P/E Ratio: 50.58
• Dividend Yield: 0.55%
• Price Target: N/A
• Consensus Rating: N/A

Sartorius Stedim Biotech Stock Analysis - MarketRank™

Sartorius Stedim Biotech scored higher than 0% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Sartorius Stedim Biotech.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Sartorius Stedim Biotech is 50.58, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.78.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sartorius Stedim Biotech is 50.58, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 22.19.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Sartorius Stedim Biotech has a short interest ratio ("days to cover") of 7.1.

Change versus previous month

Short interest in Sartorius Stedim Biotech has recently increased by 45.78%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

Sartorius Stedim Biotech has a dividend yield of 0.84%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Sartorius Stedim Biotech does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Sartorius Stedim Biotech is 27.84%. This payout ratio is at a healthy, sustainable level, below 75%.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Sartorius Stedim Biotech has a short interest ratio ("days to cover") of 7.1.

Change versus previous month

Short interest in Sartorius Stedim Biotech has recently increased by 45.78%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Sartorius Stedim Biotech this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sartorius Stedim Biotech insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 9.21% of the stock of Sartorius Stedim Biotech is held by institutions.

SDMHF Stock Analysis - Frequently Asked Questions

How have SDMHF shares performed this year?

Sartorius Stedim Biotech's stock was trading at $195.00 at the start of the year. Since then, SDMHF stock has increased by 11.8% and is now trading at $218.00.
View the best growth stocks for 2025 here.

How do I buy shares of Sartorius Stedim Biotech?

Shares of SDMHF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Medical Instruments & Supplies
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:SDMHF
• CIK: N/A
• Web: www.sartorius.com
• Phone: (344) 284-5600
• Fax: N/A
• Employees: 10,382
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: 50.58
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A